• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

高血压与中风的经济学

The economics of hypertension and stroke.

作者信息

Smith G T

机构信息

Office of Health Economics, London, England.

出版信息

Am Heart J. 1990 Mar;119(3 Pt 2):725-7; discussion 727-8. doi: 10.1016/s0002-8703(05)80052-3.

DOI:10.1016/s0002-8703(05)80052-3
PMID:2106766
Abstract

The prevention of stroke through the control of hypertension is cost-effective economically and medically. A reduced incidence of stroke generates savings to the health service in hospital and surgical costs, and the avoidance of premature mortality means survivors contribute more to the economy as a result of extra working years. In addition to financial benefits, antihypertensive agents can also improve a patient's quality of life. This can be measured with a variety of health profiles or indexes and is often expressed together with life expectancy in quality-adjusted life years. This article examines the benefits produced by the effective control of hypertension, taking data from England and Wales during the past 30 years.

摘要

通过控制高血压来预防中风在经济和医学上都是具有成本效益的。中风发病率的降低为医疗服务节省了医院和手术费用,而避免过早死亡意味着幸存者由于额外的工作年限而对经济做出更多贡献。除了经济效益外,抗高血压药物还可以改善患者的生活质量。这可以通过各种健康状况或指标来衡量,并且通常在质量调整生命年中与预期寿命一起表示。本文利用过去30年英格兰和威尔士的数据,研究了有效控制高血压所带来的益处。

相似文献

1
The economics of hypertension and stroke.高血压与中风的经济学
Am Heart J. 1990 Mar;119(3 Pt 2):725-7; discussion 727-8. doi: 10.1016/s0002-8703(05)80052-3.
2
Is the pharmacological treatment of mild to moderate hypertension cost effective in stroke prevention?轻度至中度高血压的药物治疗在预防中风方面是否具有成本效益?
N Z Med J. 1988 Apr 13;101(843):167-71.
3
Treating mild hypertension.治疗轻度高血压。
Lancet. 1985 Dec 14;2(8468):1364. doi: 10.1016/s0140-6736(85)92659-5.
4
[Stroke prevention with a high risk strategy of treating hypertension in patients after a transient ischemic attack].
Wien Med Wochenschr. 1997;147(2):34-6.
5
Cost-effective intervention in stroke.中风的经济有效干预措施。
Pharmacoeconomics. 1992 Dec;2(6):468-99. doi: 10.2165/00019053-199202060-00007.
6
Preventing strokes: considerations for developing health policy.预防中风:制定卫生政策的考量因素
Health Rep. 1994;6(1):216-23.
7
Economics of hypertension control. World Hypertension League.高血压控制经济学。世界高血压联盟。
Bull World Health Organ. 1995;73(4):417-24.
8
Lifetime health and economic benefits of weight loss among obese persons.肥胖人群体重减轻对一生健康和经济的益处。
Am J Public Health. 1999 Oct;89(10):1536-42. doi: 10.2105/ajph.89.10.1536.
9
Cost-effectiveness issues in hypertension control.高血压控制中的成本效益问题。
Can J Public Health. 1994 Sep-Oct;85 Suppl 2:S54-6.
10
The medical economics of stroke.中风的医学经济学
Drugs. 1997;54 Suppl 3:51-7; discussion 57-8. doi: 10.2165/00003495-199700543-00008.

引用本文的文献

1
Use of quality adjusted life years and life years gained as benchmarks in economic evaluations: a critical appraisal.在经济评估中使用质量调整生命年和获得的生命年作为基准:一项批判性评价。
Health Care Manag Sci. 2004 Feb;7(1):43-9. doi: 10.1023/b:hcms.0000005397.93173.bb.
2
[Value of brief questionnaires in predicting smoking cessation in primary care].[简短问卷在预测基层医疗中戒烟情况的价值]
Aten Primaria. 2000 Jan;25(1):32-6. doi: 10.1016/s0212-6567(00)78460-5.
3
Therapeutic options in the treatment of multiple myeloma: pharmacoeconomic and quality-of-life considerations.
多发性骨髓瘤治疗中的治疗选择:药物经济学及生活质量考量
Pharmacoeconomics. 1999 Oct;16(4):329-41. doi: 10.2165/00019053-199916040-00002.
4
Pharmacoeconomic aspects of treatment of acute myocardial infarction with thrombolytic agents.溶栓药物治疗急性心肌梗死的药物经济学方面
Pharmacoeconomics. 1993 Mar;3(3):192-204. doi: 10.2165/00019053-199303030-00003.
5
Cost-utility analysis of melphalan plus prednisone with or without interferon-alpha 2b in newly diagnosed multiple myeloma. Results from a randomised controlled trial.美法仑联合泼尼松加或不加α-干扰素2b治疗新诊断多发性骨髓瘤的成本效用分析。一项随机对照试验的结果
Pharmacoeconomics. 1997 Jul;12(1):89-103. doi: 10.2165/00019053-199712010-00009.
6
The economics of shared care packages.共享护理套餐的经济学
Pharmacoeconomics. 1996 Sep;10(3):197-204. doi: 10.2165/00019053-199610030-00001.
7
Novel monoclonal antiendotoxin antibody therapy: efficacy at any price?新型单克隆抗内毒素抗体疗法:不惜一切代价的疗效?
Pharmacoeconomics. 1993 Jun;3(6):437-45. doi: 10.2165/00019053-199303060-00003.
8
The problem of quality of life.生活质量问题。
Qual Life Res. 1997 Apr;6(3):205-12. doi: 10.1023/a:1026402519847.
9
Some guidelines on the use of cost effectiveness league tables.关于成本效益排行榜使用的一些指南。
BMJ. 1993 Feb 27;306(6877):570-2. doi: 10.1136/bmj.306.6877.570.